29 dec: Aktier/middag: Vestas tager bundplacering trods nye ordrer
29 dec: Skidt år for vindmølleaktier - trods god ordreaktivitet
29-12-2016 13:00:12

Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer

Relateret indhold
22 maj - 
Bavarian vil opruste Danmarks bioberedskab med koppevac..
05 maj - 
Bavarian/Jyske: Sænker til "køb"
05 maj - 
Aktier/åbning: Vestas og TDC løfter C20 tættere på himl..
Relateret debat
25 maj - 
Tak igen Enkommentar for fine tanker og opsummering. &n..
25 maj - 
Lidt opdateringer på deltagelse i Prostvac pr den..
25 maj - 
Bamse godt skrevet og fanget - mon ikke der snart blive..

  • Study is exploring potential benefits of combining a cancer vaccine and PD-1 checkpoint inhibitor

COPENHAGEN, Denmark, December 29, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the initiation of a clinical trial combining its proprietary cancer immunotherapy candidate, CV301, with the anti-PD-1 drug, OPDIVO® (nivolumab) from Bristol-Myers Squibb. The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy.

 

The trial will begin with a Phase 1 safety component, enrolling up to 40 patients; the Phase 2 portion of the study will enroll 120 patients who will be randomized to receive either nivolumab (monotherapy) or a combination of CV301 and nivolumab. The study will enroll patients from up to 20 clinical sites throughout the United States. Detailed information on the trial can be found at http://clinicaltrials.gov/ct2/show/NCT02840994.

The rationale for this combination approach is for the vaccine to generate a tumor specific T cell response and allow the checkpoint inhibitor to maintain that immune effect by preventing the tumor from turning that response off.

While the primary endpoint of the study is overall survival, numerous secondary endpoints including response rate, progression free survival and duration of response will be evaluated and offer the potential for an early efficacy signal, prior to an overall survival endpoint.

"We are pleased to announce the initiation of this study, which marks the entry for Bavarian Nordic into lung cancer. While CV301 has shown the ability to generate immune responses to tumor-associated antigens in a variety of cancers, this study is the first seeking proof-of-concept for a promising combination approach and we look forward to the results as well as to advance CV301 as combination therapy in additional indications over the next years," said Paul Chaplin, President & CEO of Bavarian Nordic.

About CV301

CV301 is an immunotherapy candidate which is being developed under a CRADA with the National Cancer Institute (NCI).

CV301 targets two tumor-associated antigens, CEA and MUC-1, which are over-expressed in multiple solid tumors, including lung, bladder and colorectal cancer. Similar to PROSTVAC®, CV301 uses a prime/boost dosing schedule. CV301 incorporates a modified version of vaccinia (MVA-BN, a proprietary technology of Bavarian Nordic) as a priming dose, followed by multiple fowlpox boosts, and encodes the TRICOM costimulatory molecules.

A precursor version of CV301 has been tested in six NCI-sponsored clinical trials in various cancers, and a Phase 2 study in bladder cancer is currently ongoing. More than 300 patients have been treated with the product candidate.

About OPDIVO (nivolumab)

Marketed by Bristol-Myers Squibb, OPDIVO is an immune checkpoint inhibitor (anti-PD-1 therapy) approved for treatment of patients with advanced NSCLC in the second line setting, among other indications. OPDIVO has demonstrated superior overall survival across histologies, versus chemotherapy, in two pivotal Phase 3 trials in patients with advanced NSCLC.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

2016-12-29-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 2016-12-29-en.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 maj
BAVA
tak til Kranen og andre, for at smide lidt guld ud i form af info.   Men guldet kom først her:   htt..
20
19 maj
BAVA
Slap dog af bamse. 1.000 i 2017 er et temmelig vildt gæt. Og det er vel at mærke et gæt, du giver jo..
15
25 maj
BAVA
Millenium har fundet ud af at det man at shorte bavarian er en rimeligt dårlig ide. De reducerer end..
9
21 maj
BAVA
Kik lige på vedlagte:   18/5 2017: https://clinicaltrials.gov/ct2/show/NCT00450463?term=prostvac&ran..
6
25 maj
BAVA
Lidt opdateringer på deltagelse i Prostvac pr den 1/6 2017 som vi jo snart når til.. For hver mdr de..
5
19 maj
BAVA
Nordea ser ud til at være enig i den betragtning. Nedenstående er morgenens flash news på nordea inv..
5
25 maj
BAVA
Ja det ser godt ud, en lille god nyhed og vi skal videre op. Jeg ved ikke med jer andre, men min for..
4
19 maj
BAVA
Det er bare fedt at Bava kom så stærkt tilbage. Dette sammen med tidligere nævnt insider tegn, gør a..
4
21 maj
BAVA
Du er da så snæversynet, som det kan lade sig gøre at være. I et tidligere indlæg i denne tråd skrev..
3
19 maj
BAVA
50 mia ville da være en fin pris. det halve er nok mere realistisk.   Men skulle det blive 50 mia, s..
3

Dong-topchef om salg af oliedivision: Den samlede pris er rigtig fin

24-05-2017 16:33:25
Flere iagttagere har kaldt salgsprisen for Dongs olie- og gasforretning lav, men hos energiselskabet selv mener man, at prisen er rigtig god, når man ser på det samlede regnestykke.Sådan lyder det fra Dongs administrerende direktør, Henrik Poulsen, efter at selskabet onsdag har gjort klar til et salg til den britiske kemikoncern Ineos.- Vi har fået en rigtig fin pris for forretningen. Vi har fået ..

Nordex-Acciona/dir: Har rigtig godt momentum i USA

24-05-2017 12:06:06
Den tyske vindmølleproducent Nordex, der for nylig overtog Acciona Windpower, har USA som et af nøglemarkederne, hvor selskabet venter at kunne fortsætte væksten fra et travlt 2017.- Vi har et rigtigt godt momentum i markedet, og i år kommer vil til at installere tæt ved 800 megawatt i USA siger Thomas Donoghue, som er salgschef for Nordex-Acciona på det nordamerikanske marked, til Ritzau Finans p..

Aktier/åbning: Salg af oliebiks sender Dong op i lyserødt marked

24-05-2017 09:07:05
Lige da alt så ud til at være ganske fredeligt før åbningen af det danske aktiemarked onsdag før den lange weekend, strøg Dong i fokus med nyheden om, at olie- og gasforretningen bliver solgt til kemivirksomheden Ineos.Dong satte forretningsdelen til salg i efteråret, og Dong har selv flere gange sagt, at et frasalg var ventet i løbet af 2017. Prisen kan løbe op i 8,7 mia. kr. og ændrer ikke ved 2..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Bavarian Nordic A/S 358,00 0,0% Aktiekurs uændret
Bavarian Nordic DKK10 53,40 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. maj 2017 13:12:50
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170517.1 - EUROWEB2 - 2017-05-26 13:12:50 - 2017-05-26 13:12:50 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x